GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xcell Therapeutics Inc (XKRX:373110) » Definitions » Other Gross PPE

Xcell Therapeutics (XKRX:373110) Other Gross PPE : ₩1,883 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Xcell Therapeutics Other Gross PPE?

Xcell Therapeutics's Other Gross PPE for the quarter that ended in Sep. 2024 was ₩1,883 Mil.

Xcell Therapeutics's quarterly Other Gross PPE declined from Mar. 2024 (₩2,213 Mil) to Jun. 2024 (₩2,037 Mil) and declined from Jun. 2024 (₩2,037 Mil) to Sep. 2024 (₩1,883 Mil).

Xcell Therapeutics's annual Other Gross PPE declined from Dec. 2021 (₩2,268 Mil) to Dec. 2022 (₩1,858 Mil) but then increased from Dec. 2022 (₩1,858 Mil) to Dec. 2023 (₩2,809 Mil).


Xcell Therapeutics Other Gross PPE Historical Data

The historical data trend for Xcell Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcell Therapeutics Other Gross PPE Chart

Xcell Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
1,603.35 1,295.56 2,268.32 1,857.98 2,808.96

Xcell Therapeutics Quarterly Data
Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Gross PPE Get a 7-Day Free Trial - 2,808.96 2,213.16 2,037.31 1,882.56

Xcell Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Xcell Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
333, Yeongdong-daero, Gangnam-gu, Seoul, KOR, 06188
Xcell Therapeutics Inc operates as a research company engaged in development of regenerative medicines. The company is developing proliferation media for various animal cell types.

Xcell Therapeutics Headlines

No Headlines